<DOC>
	<DOC>NCT02038621</DOC>
	<brief_summary>To confirm the efficacy and safety of XELOX with capecitabine maintenance in treatment of advanced gastric cancer (AGC)</brief_summary>
	<brief_title>The Maintenance Therapy of Capecitabine of Advanced Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Age ≥ 18 years old male or female Patients with stage IV gastric cancer by pathology or cytology and imaging diagnosis , or after previous surgery or radiotherapy or chemotherapy in patients with stage IV gastric cancer progression , there RECIST criteria evaluable lesions ; ECOG performance status score 02 ; Expected survival time more than three months ; Adequate hematologic parameters and liver and kidney function ; Bone marrow : absolute neutrophil count (ANC) ≥ 1.5 × 109 / L, platelets ≥ 75 × 109 / L, hemoglobin ≥ 80g / L; Liver: bilirubin ≤ 1.5 times the upper limit of normal , ALT AST values ≤ 2.5 times the upper limit of normal ; Renal : serum creatinine ≤ ULN ; Informed consent of patients or their agents , and signed informed consent. For patients allergic to capecitabine ; Patients with CNS metastases Undermine the integrity of the upper gastrointestinal tract , malabsorption syndrome , or unable to take oral medication ; Patients with coronary heart disease , angina , myocardial infarction , arrhythmia, cerebral thrombosis, stroke and other serious cardiovascular and cerebrovascular disease ; Or in combination with other antitumor therapy in patients participating in clinical trials of other interventions ; Pregnancy or breastfeeding patients , or fertility without taking adequate contraceptive measures were ; The researchers believe that this test is not suitable for those who participate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>